Council Members in this Study Group: 49
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Leading institutions connect with members of this Study Group through GLG
Donald FlemingDivision Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC![]()
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed...
Taral PatelOncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INC![]()
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer,...
Al BarqawiAssistant Professor
University of Colorado Health Sciences Center - CC![]()
Al Barqawi, MD, FRCS, is Assistant Professor and Lecturer in the Division of Urology at University of Colorado Health Science Center. Dr. Barqawi also serves as Director of Research in the Section of Urologic Oncology. He has expertise in urologic oncology...
Eric WhitmanMedical Director, Office of Grants and Research
ATLANTIC HEALTH SYSTEM INC![]()
Eric Whitman, MD, is the Medical Director of the Office of Grants and Research for Atlantic Health System in Morristown, New Jersey. He is a board certified General Surgeon with fellowship training in surgical oncology. He specializes in melanoma care,...
January 30, 2010
Roche gets EU approval for Herceptin to treat HER2-positive advanced stomach cancer | www.pharmabiz.com
There has been between a 20-30% Her over expression detected on adeno ca of gastric mucosaThe fastest growing esophageal malignancy is GE junction adenoca, which acts and is treated very similar to adeno ca of stomachOther solid tumors are likely to also demonstrate a similar benefit
December 16, 2009
BiPar Sciences' BSI-201 phase-3 trial makes progress in metastatic triple-negative breast cancer | www.pharmabiz.com
Recent evidence suggest that PARP is a new enzyme related target for TNBCTNBC sorely needs more effective therapyBe certain, the PARP target is not TNBC specific
December 10, 2009
Novartis' Tasigna demonstrates greater efficacy over Glivec in chronic myeloid leukaemia | www.pharmabiz.com
Gleevec has revolutionized outcome/ therapy in CMLRecent phase III demonstrates better tolerance of Tasigna over GleevecCML outcome is reflected in MR and Tasigna seems to do it better
Roche's Avastin declined by European "bean counters" for brain tumor
November 23, 2009
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer | www.pipelinereview.com
Avastin utilized successfully in US for primary brain tumors, including the very aggressive GBMHealth care, including cancer, will be all about rationingRoche and other pharma companys better get ready for a rough future
November 14, 2009
US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com
Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients